Grassley suggests that the NIH ensure that the definition of the term "significant financial interest" include pharmaceutical and device company financing and/or other material contribution or support to develop medical literature including, but not limited to, conceiving and designing the underlying paper, collecting and/or analyzing the data, and drafting, reviewing and/or revising the manuscript. The term should also include pharmaceutical and device company payments to any NIH-supported researcher for writing, editing or contributing to an article published in a medical journal or other medical or research publication."

In addition, Grassely says, NIH should require that institutions receiving NIH grants maintain policies on the authorship of articles and the disclosure of any financial or material support provided by a drug or device company to any articles written by or attributed to the NIH.


The staff report: http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf

Grassley's letter to the NIH: http://grassley.senate.gov/about/upload/2010-06-24-Letter-to-NIH.pdf

Back to HCB News

More Industry Headlines